Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis [0.03%]
初治人类免疫缺陷病毒(HIV)感染者使用替诺福韦的疗效比较：系统评价和meta分析
Lars G Hemkens,Hannah Ewald,Marilia Santini-Oliveira et al.
Lars G Hemkens et al.
Introduction: Benefits and harms of tenofovir disoproxil fumarate (TDF) in HIV-infected, antiretroviral treatment (ART)-naïve patients of any age have not been systematically reviewed since recent milestone trials were p...
Increased CD38 expression on T lymphocytes as a marker of HIV dissemination into the central nervous system [0.03%]
T淋巴细胞上CD38表达增加作为HIV向中枢神经系统扩散的标志物
Chiara Dentone,Daniela Fenoglio,Eva Schenone et al.
Chiara Dentone et al.
Cross-sectional analysis on 20 HIV-1 patients with neurological symptoms admitted to two infectious disease units. Cut-off of HIV-RNA (VL) was 20 copies/ml for plasma and cerebral spinal fluid (CSF). Flow cytometry was used to analyze the p...
Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir [0.03%]
马拉维若和多替拉韦随机对照试验中CD4⁺细胞反应的缺失
Robert Cuffe,Carly Barnett,Catherine Granier et al.
Robert Cuffe et al.
Background: Missing data can compromise inferences from clinical trials, yet the topic has received little attention in the clinical trial community. Shortcomings in commonly used methods used to analyze studies with miss...
Clinical Trial
HIV clinical trials. 2015 Oct;16(5):170-7. DOI:10.1179/1945577115Y.0000000003 2015
Effects of raltegravir combined with tenofovir/emtricitabine on body shape, bone density, and lipids in African-Americans initiating HIV therapy [0.03%]
拉替拉韦与替诺福韦/恩曲他滨对开始治疗的人类免疫缺陷病毒阳性非洲裔美国人躯体、骨密度和血脂的影响
Laura Young,David A Wohl,William B Hyslop et al.
Laura Young et al.
Background: Raltegravir (RAL) plus tenofovir/emtricitabine (TDF/FTC) is a recommended initial antiretroviral regimen. A substantial proportion of persons diagnosed with HIV infection and starting antiretrovirals in the U....
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity [0.03%]
HIV挽救治疗OPTIONS方案选择试验：药物耐药性、既往治疗和种族因素决定治疗方案的复杂程度
Karen T Tashima,Katie R Mollan,Lumine Na et al.
Karen T Tashima et al.
Background: Regimen selection for highly treatment-experienced patients is complicated. Methods: Using a web-based utility, study team ...
Clinical Trial
HIV clinical trials. 2015 Aug;16(4):147-56. DOI:10.1179/1945577115Y.0000000001 2015
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine [0.03%]
接受阿扎那韦/利托那韦和阿巴卡韦/拉米夫定或简化为未增效的阿扎那韦/阿巴卡韦/拉米夫定治疗的HIV-1感染者长达108周的肾小球滤过率估算值
Benjamin Young,Kathleen E Squires,Karen Tashima et al.
Benjamin Young et al.
Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope [0.03%]
源自HIV-1基质蛋白p17功能表位的合成肽(AT20)在HIV-1感染者中诱导长时间体液免疫反应
Emanuele Focà,Maria Luisa Iaria,Francesca Caccuri et al.
Emanuele Focà et al.
Objective: A therapeutic vaccination based on a synthetic peptide (AT20) representative of the HIV-1 matrix protein p17 (p17) functional region, coupled to keyhole limpet hemocyanin (KLH) AT20-KLH was capable of inducing ...
Observational Study
HIV clinical trials. 2015 Aug;16(4):157-62. DOI:10.1179/1528433614Z.0000000018 2015
HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts [0.03%]
HIV和冠状动脉钙化积分：夏威夷HIV感染患者心血管研究与多民族动脉粥样硬化研究队列比较
Dominic Chow,Rebekah Young,Nicole Valcour et al.
Dominic Chow et al.
Objectives: To determine the association of HIV, immunologic, and inflammatory factors on coronary artery calcium (CAC), a marker of subclinical atherosclerosis. ...
Clinical Trial
HIV clinical trials. 2015 Aug;16(4):130-8. DOI:10.1179/1528433614Z.0000000016 2015
Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054) [0.03%]
在挽救治疗方案中去除无效的NRTIs是安全的，可维持病毒抑制并减少治疗费用：VERITAS研究(TMC114HIV4054)的结果
Benoit Trottier,Chrissi Galanakis,Danièle Longpré et al.
Benoit Trottier et al.
Background: Despite the benefit of maintaining inactive Nucleotide/side reverse transcriptase inhibitors (NRTIs) in salvage regimens, they are associated with increased toxicity and treatment costs. Current evidence sugge...
Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial [0.03%]
在多国随机临床试验中性别不同的抗逆转录疗效和安全性差异
Cynthia Firnhaber,Laura M Smeaton,Beatriz Grinsztejn et al.
Cynthia Firnhaber et al.
Background and objective: Worldwide, 50% of human immunodeficiency virus (HIV)-infected people are women. This study was to evaluate whether the safety and efficacy outcomes of three initial antiretroviral regimens (ARVs)...
Randomized Controlled Trial
HIV clinical trials. 2015 May-Jun;16(3):89-99. DOI:10.1179/1528433614Z.0000000013 2015